:: Volume 21, Number 5 (9-2017) ::
IBJ 2017, 21(5): 321-329 Back to browse issues page
Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer
Yeganeh Talebkhan, Mohsen Doozbakhshan, Samaneh Saberi, Maryam Esmaeili, Najmeh Karami, Nazanin Mohajerani, Afshin Abdirad, Mahmoud Eshagh Hosseini, Azin Nahvijou, Mohammad Ali Mohagheghi, Marjan Mohammadi
Abstract:  

Background: Gastric cancer arises, mainly, on an inflammatory background. Helicobacter pylori neutrophil activating (HP-NAP) protein functions as a potent pro-inflammatory mediator.  Similarly, IL-4 plays a critical role in the inflammation pathway, the levels of which are altered by C to T transition at position -590 in its promoter region. Here, we have aimed to assess the risk of gastritis and gastric cancer in the co-presence of these two inflammation modulating mediators. Methods: Gastritis (n=58) and gastric cancer (n=31) patients were evaluated and compared with H. pylori-positive asymptomatic controls (n=46), for serum antibodies against recombinant HP-NAP and IL-4 C-590T single nucleotide polymorphism using immunoblotting and PCR-RFLP, respectively. Multivariable logistic regression, adjusting for age, gender and ethnicity, was used for data analysis. Results: In terms of susceptibility to gastritis, seropositivity to HP-NAP projected a risk impact of 4.62 fold (OR=4.62, 95% CI=1.50-14.22), which when present in IL-4 -590 T carriers augmented the risk up to 9.7 fold (OR=9.70, 95% CI=2.06-45.69). A similar pattern, but of a stronger magnitude, occurred for the risk of gastric cancer, which was estimated at 9.07 fold (OR=9.07, 95% CI=1.99-42.0) for HP-NAP-seropositive subjects and was drastically amplified (OR=33.64, 95% CI=2.06-548.68), when double-positive (HP-NAP seropositive/IL-4 -590 T carrier) subjects were examined against double negatives (HP-NAP seronegative/IL-4 -590 CC). Conclusion: Our preliminary data indicate that serum antibodies against HP-NAP represent a state of risk, which is further exacerbated in IL-4 -590 T carriers. These biomarkers, if validated in larger prospective studies, can be used to screen for gastric cancer susceptibility.

Keywords: Biomarkers, Genetic Polymorphism, Recombinant
Full-Text [PDF 651 kb]      
Type of Study: Full Length | Subject: Molecular Immunology & Vaccines
Add your comments about this article
Your username or email:

Write the security code in the box >



DOI: 10.18869/acadpub.ibj.21.5.321
PMID: 27677314


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Talebkhan Y, Doozbakhshan M, Saberi S, Esmaeili M, Karami N, Mohajerani N, et al . Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer. IBJ. 2017; 21 (5) :321-329
URL: http://ibj.pasteur.ac.ir/article-1-1895-en.html
Volume 21, Number 5 (9-2017) Back to browse issues page
Persian site map - English site map - Created in 0.173 seconds with 887 queries by yektaweb 3455